Gossamer Bio, Inc.
GOSS
$1.45
$0.1511.54%
| Weiss Ratings | GOSS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | GOSS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | GOSS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.29 | |||
| Price History | GOSS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 22.88% | |||
| 30-Day Total Return | 50.46% | |||
| 60-Day Total Return | 55.91% | |||
| 90-Day Total Return | 65.15% | |||
| Year to Date Total Return | 49.48% | |||
| 1-Year Total Return | 3.57% | |||
| 2-Year Total Return | 3.57% | |||
| 3-Year Total Return | -83.56% | |||
| 5-Year Total Return | -84.82% | |||
| 52-Week High % Change | -16.13% | |||
| 52-Week Low % Change | 160.36% | |||
| Price | GOSS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $1.55 | |||
| 52-Week Low Price | $0.50 | |||
| 52-Week Low Price (Date) | Jun 10, 2024 | |||
| 52-Week High Price (Date) | Feb 20, 2025 | |||
| Valuation | GOSS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 294.59M | |||
| Enterprise Value | 171.18M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.32 | |||
| Earnings Per Share Growth | -81.75% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 2.79 | |||
| Price/Book (Q) | 5.44 | |||
| Enterprise Value/Revenue (TTM) | 1.63 | |||
| Price | $1.45 | |||
| Enterprise Value/EBITDA (TTM) | -2.77 | |||
| Enterprise Value/EBIT | -2.72 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | GOSS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 226.35M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | GOSS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 684 1300 | |||
| Address | 3013 Science Park Road San Diego, CA 92121 | |||
| Website | www.gossamerbio.com | |||
| Country | United States | |||
| Year Founded | 2015 | |||
| Profitability | GOSS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -59.64% | |||
| Profit Margin | -68.02% | |||
| Management Effectiveness | GOSS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -11.24% | |||
| Return on Equity | -- | |||
| Income Statement | GOSS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 105.32M | |||
| Total Revenue (TTM) | 105.32M | |||
| Revenue Per Share | $0.47 | |||
| Gross Profit (TTM) | 105.32M | |||
| EBITDA (TTM) | -61.80M | |||
| EBIT (TTM) | -62.82M | |||
| Net Income (TTM) | -71.65M | |||
| Net Income Avl. to Common (TTM) | -71.65M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 23.01% | |||
| EPS Diluted (TTM) | -0.32 | |||
| EPS Diluted Growth (Q YOY) | 34.38% | |||
| Balance Sheet | GOSS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 327.03M | |||
| Cash Per Share (Q) | $1.44 | |||
| Total Current Assets (Q) | 344.27M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 54.14M | |||
| Current Ratio (Q) | 6.739 | |||
| Book Value Per Share (Q) | $0.24 | |||
| Total Assets (Q) | 350.88M | |||
| Total Current Liabilities (Q) | 51.09M | |||
| Total Debt (Q) | 203.63M | |||
| Total Liabilities (Q) | 296.74M | |||
| Total Common Equity (Q) | 54.14M | |||
| Cash Flow | GOSS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -38.56M | |||
| Cash from Financing (TTM) | -14.39M | |||
| Net Change in Cash (TTM) | -54.15M | |||
| Levered Free Cash Flow (TTM) | -2.63M | |||
| Cash from Operations (TTM) | -1.41M | |||
